Regulation of the Release of Inflammatory Mediators From Blood Leukocytes

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Imperial College London.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Asthma UK
Information provided by:
Imperial College London
ClinicalTrials.gov Identifier:
NCT00180765
First received: September 13, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
  Purpose

Chronic obstructive pulmonary disease (COPD for short) involves inflammation inside the air passages of the lungs. This inflammation might be partly responsible for the shortness of breath, cough and susceptibility to chest infections that form part of COPD. Inflammation is caused, in part, by white blood cells that are attracted from the blood into the air passages. Once inside the air passages, the white blood cells may change (or ‘differentiate’) and release substances that produce inflammation and attract more white cells. The hypothesis is that the lifespan of these cells may also be prolonged such that they produce more inflammatory mediators and in turn perpetuate inflammation. The cycle of inflammation may damage the lungs, so we want to see what mediators are released by white blood cells and determine if we can inhibit this effect with existing and new drugs. We would also like to see the effect of these drugs on the life-span and function of white blood cells. We will compare the behaviour and characteristics of white cells with those from healthy smokers and healthy non-smokers to find out if there is anything different about cells from COPD patients.


Condition Intervention
Chronic Obstructive Airway Disease
Healthy Volunteers
Procedure: Up to 100ml blood will be taken by venupuncture.

Study Type: Observational
Study Design: Observational Model: Natural History
Time Perspective: Cross-Sectional
Official Title: Regulation of the Release of Inflammatory Mediators From Blood Leukocytes: A Comparison of Healthy Subjects, Healthy Smokers and Patients With COPD.

Resource links provided by NLM:


Further study details as provided by Imperial College London:

Estimated Enrollment: 30
Study Start Date: October 2001
Estimated Study Completion Date: February 2008
Detailed Description:

The aim of this study is to investigate the mechanisms that regulate the survival of blood leukocytes as well as the synthesis and release of inflammatory mediators from cells from normal individuals and subjects with COPD. The hypothesis is that in COPD the life-span of leukocytes, such as the neutrophil, is enhanced and this may contribute to inflammation, a prominent characteristic of this disease, by secreting and releasing inflammatory mediators. We also suggest that differences may exist in the sensitivity of the various leukocytes to different therapies.

Leukocytes will be purified from the peripheral venous blood of patients with COPD as well as healthy individuals. We will then investigate the effects of novel and existing therapeutic agents on leukocyte survival and inflammatory mediator synthesis and release. We will also examine the regulation and release of enzymes known to damage lung tissue. Further studies will be carried out to elucidate the signal transduction pathways that lead to the activation, altered longevity and function of leukocytes. In other experiments ribonucleic acids or RNA may be extracted form leukocytes to investigate which genes are involved. The primary objective is to identify the mechanisms that enhance leukocyte longevity and inflammatory mediator and/or enzyme synthesis and release with a view to identifying novel targets for drug therapy.

  Eligibility

Ages Eligible for Study:   21 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Healthy non-smoking subjects: All normal volunteers will meet the following criteria:

  • Age 21-70 years.
  • No history of respiratory or allergic disease.
  • Normal baseline spirometry as predicted for age, sex and height.
  • Non-smokers.
  • No history of upper respiratory tract infection in the preceding six weeks.
  • Not taking regular medication

COPD subjects: COPD is diagnosed according to American Thoracic Society, European Respiratory Society and British Thoracic Society guidelines by the doctors in Professor Barnes’ COPD clinic. All COPD volunteers will meet the following criteria:

  • Age between 40-75 years.
  • A smoking history of at least 20 pack years. ( 1 pack year = 20 cigarettes per day for 1 year)
  • FEV1:FVC ratio of <0.7, post-bronchodilator FEV1 of <85% predicted, reversibility with inhaled b2-agonist of <15% of predicted FEV1: all three criteria are required.
  • Current smokers or smokers who had ceased smoking for at least 6 months.
  • No history of exacerbation, oral steroid or antibiotic use within the preceding 6 weeks.
  • Normal serum a-1 antitrypsin level.
  • No history of other respiratory or allergic disease.
  • No evidence of atopy on skin prick testing to common aeroallergens (grass pollen, cat hair, house dust mite or Aspergillus fumigatus
  • These tests will have already been performed as part of routine assessment in Professor Barnes’ COPD clinic and we will not need to repeat them for this study.

Healthy Smokers: All healthy smoking volunteers in trials will meet the following criteria:

  • Age 21-70 years.
  • Smoking history of at least 10 pack years (1 pack year = 20 cigarettes per day for 1 year).
  • No history of respiratory or allergic disease.
  • Normal baseline spirometry as predicted for age, sex and height.
  • No history of upper respiratory tract infection in the preceding six weeks.
  • Not taking regular medication.

Exclusion Criteria:

Subjects will not included in this study if they meet any of the following exclusion criteria:

  • Clinically significant findings in the medical history or on physical examination other than those of COPD in the COPD group.
  • Pregnant women or mothers who are breastfeeding.
  • Subjects who are unable to give informed consent.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00180765

Contacts
Contact: Patricia M de Souza, PhD 0207 352 8121 ext 3027 p.desouza@imperial.ac.uk

Locations
United Kingdom
National Heart & Lung Institute, Imperial College Recruiting
Chelsea, London, United Kingdom, SW3 6LY
Contact: Patricia M de Souza, PhD    0207 352 8121 ext 3027    p.desouza@imperial.ac.uk   
Sub-Investigator: Patricia M de Souza, PhD         
Sub-Investigator: Susan J Smith, PhD         
Sub-Investigator: Xiao-ju Liu, PhD         
Sponsors and Collaborators
Imperial College London
Asthma UK
Investigators
Principal Investigator: Peter J Barnes, DSc National Heart & Lung Institute, Imperial College
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00180765     History of Changes
Other Study ID Numbers: 01-215
Study First Received: September 13, 2005
Last Updated: September 13, 2005
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by Imperial College London:
Leukocytes
Eosinophils
Neutrophils
Chronic Obstructive Airway Disease
Apoptosis
Signal Transduction

Additional relevant MeSH terms:
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 21, 2014